GSK to Use Response Genetics' PCR Technology to Develop Companion Diagnostics for Cancer Drugs

The drug company intends to apply the technology to develop companion diagnostics for BRAF and MEK inhibitors currently under development.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.